The resurgent U.S. housing market has sent builders calling again for Richard Vap, who owns a drywall installation company. Vap would love to help -- if he could hire enough qualified people.
"There is a shortage of manpower," says Vap, owner of South Valley Drywall in Littleton, Colo. "We're probably only hiring about 75 or 80 percent of what we actually need."
U.S. builders and the subcontractors they depend on are struggling to hire fast enough to meet rising demand for new homes. Builders would be starting work on more homes -- and contributing more to the economy -- if they could fill more job openings.
In the meantime, workers in the right locations with the right skills are commanding higher pay.
The shortage of labor ranges across occupations -- from construction superintendents and purchasing agents to painters, cabinet makers, and drywall installers. The National Association of Home Builders says its members have complained of too few framers, roofers, plumbers, and carpenters. The shortage is most acute in areas where demand for new homes has recovered fastest, notably in Arizona, California, Texas, Colorado, and Florida.
Top 10 Blue Chip Companies To Invest In Right Now: Southwestern Energy Company(SWN)
Southwestern Energy Company, an independent energy company, engages in the exploration, development, and production of natural gas and crude oil in the United States. The company operates through two segments, Exploration and Production, and Midstream Services. The Exploration and Production segment involves in the development of an unconventional gas reservoir located on the Arkansas side of the Arkoma Basin, as well as exploration and production activities in Texas, Pennsylvania, and Oklahoma. This segment also conducts conventional drilling programs in the Arkoma Basin; and development drilling and exploration programs in the Oklahoma portion of the Arkoma Basin, as well as in Texas and Pennsylvania. In addition, it operates drilling rigs in the Fayetteville Shale play, as well as in other operating areas; and explores for natural gas and crude oil under 32 licenses in New Brunswick, Canada. The Midstream Services segment engages in gathering, marketing, and transportin g natural gas in Arkansas, Texas, and Pennsylvania. As of December 31, 2010, the company?s estimated proved natural gas and oil reserves were approximately 4,937 billion cubic feet of natural gas equivalent. Southwestern Energy Company was founded in 1929 and is based in Houston, Texas.
Advisors' Opinion:- [By Jake L'Ecuyer]
Southwestern Energy Co (NYSE: SWN) was also up, gaining 4.41 percent to $38.86 after the company reported Q3 financial and operating results. Stifel Nicolaus upgraded the stock from Hold to Buy.
- [By Aaron Levitt]
Exxon shares are tantalizing value based on various metrics. XOM currently trade at a forward P/E just north of 12 — roughly a 23% discount to the broad market�� forward multiple. The valuation is cheaper than many of its large integrated rivals and even cheaper when compared to U.S. shale-focused independent E&P firms like Southwestern Energy (SWN). Meanwhile, other metrics like price-to-book value and price-to-sales also tilt towards XOM�� favor.
- [By Arjun Sreekumar]
Will gas producers be able to keep up?
The answer, according�to Jim Tramuto, vice president of governmental and regulatory affairs for Southwestern Energy (NYSE: SWN ) , is a resounding yes. Speaking at the 2013 U.S. Energy Information Administration Energy Conference in Washington earlier this week, he expressed great confidence about the size of the U.S. shale gas resource base. - [By Taylor Muckerman and Joel South]
Several companies on the production side, such as Southwestern Energy (NYSE: SWN ) and Sandridge Energy (NYSE: SD ) , have begun addressing this problem. From a services standpoint, Halliburton (NYSE: HAL ) is pioneering multiple, different applications that producers can choose from to both ease the stress on the environment and reduce overall costs.
5 Best Heal Care Stocks To Watch Right Now: Epizyme Inc (EPZM)
Epizyme, Inc., incorporated on November 1, 2007, is a clinical stage biopharmaceutical company that discovers, develops and plans to commercialize personalized therapeutics for patients with genetically defined cancers. The Company systematically identify the genetic alterations that create cancer causing genes, called oncogenes, select patients in whom the identified genetic alteration is found and then design small molecule therapeutics to inhibit the oncogene. The clinical development plan for each of its product candidates is directed towards patients with a particular genetically defined cancer.The Company is conducting a Phase I clinical trial of its advanced product candidate, EPZ-5676, an inhibitor targeting the DOT1L HMT, for the treatment of mixed lineage leukemia (MLL-r). The Company has identified its two lead product candidates using its product platform.
EPZ-5676-DOT1L Inhibitor
EPZ-5676 is an intravenously administered small molecule inhibitor of DOT1L. The Company is developing EPZ-5676 for the treatment of MLL-r, an aggressive subtype of the two most common forms of acute leukemia, ALL and AML. Patients with MLL-r are routinely diagnosed with existing technologies that are commonly used in clinical setting. The Company�� Phase 1 clinical trial of EPZ-5676 is an open label, multicenter trial that has two phases.
EPZ-6438-EZH2 Inhibitor
The Company is developing EPZ-6438 as an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients who have an oncogenic point mutation in EZH2. EZH2 is an HMT that can become oncogenic and cause non-Hodgkin lymphoma and a range of other solid tumors. Two types of non-Hodgkin lymphoma, diffuse large B-cell lymphoma of germinal-center origin, or DLBCL, and follicular lymphoma, or FL, are particularly associated with an EZH2 point mutation. There are no therapies approved specifically for the treatment of cancer associated with an EZH2 point mutation.
Advisors' Opinion:- [By Laura Brodbeck]
Friday
Earnings Expected From: Epizyme (NASDAQ: EPZM), Dyax Corp (NASDAQ: DYAX) Economic Releases Expected: ��German GDP, German business climate index, Italian retail sales.Get all the #premarket info by listening in to Benzinga's morning show at 8:00 am EST Monday-Friday!
- [By Jake L'Ecuyer]
Epizyme (NASDAQ: EPZM) shot up 54.63 percent to $31.70 after the company reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.
- [By John Udovich] Follow-on Stock Offerings From Small Cap Biotech Stocks. Thanks to the boom in biotech IPOs along with the sector�� overall performance, already listed biotechs have the option to ask investors for more cash in the form of a follow-on offering. Recently, FierceBiotech.com noted how four small cap biotechs raised $276 million from follow-on offerings in just one day last week. These small caps�included Epizyme Inc (NASDAQ: EPZM) which raised $88 million, Halozyme Therapeutics, Inc (NASDAQ: HALO) which raised $100 million, Agenus Inc (NASDAQ: AGEN) which raised $52 million and Idera Pharmaceuticals Inc (NASDAQ: IDRA) which raised $36 million. FierceBiotech.com noted that the�steady flow of about $4.5 billion a year in venture cash�along with�more than $3.5 billion from IPOs last year plus all of the�follow-ons are helping to foster both company growth and�accelerate drug�development programs. Mixed Bag for Biotech IPOs. Last Wednesday also saw two small cap biotech IPOs fizzle in one day�with small cap T cell vaccine developer�Genocea Biosciences Inc (NASDAQ: GNCA) raising $60 million but then ending the day down 8.3% to close at $11 while Dutch drug developer uniQure NV (QURE) raised $81.9 million but fell more than 14% to $14.61. However, orphan drug stock Auspex Pharmaceuticals Inc (NASDAQ: ASPX), which is developing�drugs to treat orphan diseases like Tourette syndrome, saw a 30.5% gain to close at $15.66 and raise $84 million. The Boston Globe quoted Michael Ringel, a partner and managing director at Boston Consulting Group who focuses on health care business, as saying:
��he mood is incredibly positive. Capital is flowing. [The biotech IPOs]��have been burning hot. I think it�� too early to suggest that is changing. I can�� predict the overall economy any better than anyone else, but I would expect a pretty good year for IPOs.��/p>
- [By Ben Levisohn]
3. We see 23+ partnered pipeline assets and are most positive on Phase I/II MOR202 anti-CD38 for myeloma with data in 2015, and others such as Acceleron Pharma (XLRN), Agios Pharmaceuticals (AGIO), Epizyme (EPZM), Concert Pharmaceuticals (CNCE) (just started Phase I for next-gen Revlimid).
5 Best Heal Care Stocks To Watch Right Now: Sao Martinho SA (SMTO3)
Sao Martinho SA is a Brazil-based holding company primarily engaged in the sale and production of sugar and ethanol. It is engaged in the cultivation of sugar cane and production and sale of sugar, ethanol and other sugar cane products. The Company is also involved in the cogeneration of electricity and cattle breeding, as well as the provision of agricultural products. The Company produces hydrous ethanol, anhydrous ethanol, industrial ethanol, ribonucleic acid, fuel oil, yeast, sugar and sugarcane biogases, used to generate steam and electricity. Through its subsidiary Omtek, the Company produces ribonucleic acid (RNA) sodium salt, which is used in the pharmaceutical and food industries as a raw material and flavor enhancer. The Company operates through a numerous subsidiaries, including Vale do Mogi Empreendimentos Imobiliarios SA, SMA Industria Quimica SA, Usina Santa Luiza SA, Sao Martinho Energia SA and Santa Cruz SA, among others. Advisors' Opinion:- [By Ney Hayashi]
Sugar and ethanol producer Sao Martinho SA (SMTO3) fell 1.8 percent to 25.53 reais after posting a quarterly profit that missed analysts��estimates.
5 Best Heal Care Stocks To Watch Right Now: Cellcom Israel Ltd.(CEL)
Cellcom Israel Ltd. provides cellular communications services in Israel. It offers basic and advanced cellular telephone services, text and multimedia messaging services, and advanced cellular content and data services. The company?s basic cellular telephony services include voice mail, cellular fax, call waiting, call forwarding, caller identification, collect call, conference calling, ?Talk 2?, additional number services, and collect call services; and outbound and inbound roaming services. It also provides value-added services comprising Cellcom volume that includes downloadable content, such as music, games, on-net-reality programs, drama series, and video games; SMS and MMS services to send and receive text, photos, multimedia, and animation messages; access to third party application providers for notification of roadway speed detectors, mange vehicle fleets, and enable subscribers to manage and operate time clocks and various controllers for industrial, agricultural , and commercial purposes; video calls to communicate with each other through video applications; zone services for calls initiated from a specific location; location-based services; voice-based information services; text-based information services and interactive information services, including news headlines, sports results, and traffic and weather reports; and data services to access handsets, cellular modems, laptops, tablets, and cellular routers, as well as Internet based payment services. In addition, the company sells handsets, modems, routers, tablets, and laptops, as well as provides repair and replacement services; and offers landline telephony, transmission, and data services through its approximately 1,500 kilometers of inland fiber-optic infrastructure and complementary microwave links to selected business customers. As of March 31, 2011, it provided its services to approximately 3.395 million subscribers. The company was founded in 1994 and is headquartered in Netanya, Israel.
Advisors' Opinion:- [By Rich Smith]
Cellcom Israel (NYSE: CEL ) is getting a new CFO.
Following the company's successful merger with Netvision, current Chief Financial Officer Yaacov Heen is declaring his mission accomplished, and says he intends to resign his post on Sept. 17 after 16 years with the company. At that time, Cellcom says it will bring on Shlomi Fruhling, the former VP for strategy and finance at Netvision, to become the merged company's new CFO on Sept. 18.
No comments:
Post a Comment